AstraZeneca breast cancer pill fails pivotal trial — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- AstraZeneca announced Friday that its breast cancer pill camizestrant failed in the SERENA-4 pivotal trial, where it was tested as a first-line therapy for advanced tumors.
- Camizestrant, given in combination with another medicine, did not outperform standard treatment on progression-free survival — the measure of how long patients lived before their cancer worsened.
- The SERENA-4 trial enrolled patients with ER-positive, HER2-negative advanced cancer who had not previously received another systemic therapy for advanced disease.
- Camizestrant, branded as Etcamah, had just won accelerated U.S. approval earlier this month — but only for patients whose tumors develop a specific mutation signaling emerging drug resistance.
- A successful SERENA-4 result could have opened a much larger market for the drug, but the failure now limits camizestrant's use to its narrower already-approved indication.
- The setback narrows the commercial scope of a drug AstraZeneca had been positioning for a far broader first-line patient population.
Why it matters: AstraZeneca already had accelerated U.S. approval for camizestrant (as Etcamah) in a narrow drug-resistance setting, but SERENA-4 was the trial meant to expand it into the much larger first-line advanced breast cancer population. That expansion just fell through, leaving the drug's market confined to the smaller mutation-driven niche and weakening AstraZeneca's competitive position in ER-positive breast cancer.
Ask SkimNews
